Novartis AG
NVSEF
$106.50
-$3.64-3.30%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.72B | 50.32B | 48.59B | 47.55B | 46.47B |
| Total Other Revenue | 1.50B | 1.41B | 1.35B | 1.31B | 1.26B |
| Total Revenue | 53.22B | 51.72B | 49.94B | 48.86B | 47.73B |
| Cost of Revenue | 12.95B | 12.82B | 12.08B | 11.95B | 12.13B |
| Gross Profit | 40.27B | 38.90B | 37.86B | 36.91B | 35.61B |
| SG&A Expenses | 12.78B | 12.56B | 12.48B | 12.44B | 12.44B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 261.00M | 487.00M | -103.00M | 182.00M | 284.00M |
| Total Operating Expenses | 35.63B | 35.57B | 31.78B | 33.44B | 33.70B |
| Operating Income | 17.59B | 16.16B | 18.16B | 15.42B | 14.03B |
| Income Before Tax | 14.92B | 13.64B | 12.73B | 10.90B | 9.73B |
| Income Tax Expenses | 2.06B | 1.70B | 975.00M | 814.00M | 622.00M |
| Earnings from Continuing Operations | 12.86K | 11.94K | 11.76K | 10.09K | 9.11K |
| Earnings from Discontinued Operations | -- | -- | 5.84B | 6.09B | 6.14B |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.00M | 2.00M | 4.00M | -2.00M | -3.00M |
| Net Income | 12.86B | 11.94B | 17.60B | 16.18B | 15.25B |
| EBIT | 17.59B | 16.16B | 18.16B | 15.42B | 14.03B |
| EBITDA | 20.92B | 19.50B | 22.49B | 19.90B | 18.65B |
| EPS Basic | 6.43 | 5.92 | 8.63 | 7.90 | 7.42 |
| Normalized Basic EPS | 5.30 | 4.80 | 5.38 | 4.51 | 4.08 |
| EPS Diluted | 6.39 | 5.88 | 8.58 | 7.86 | 7.38 |
| Normalized Diluted EPS | 5.26 | 4.77 | 5.34 | 4.48 | 4.05 |
| Average Basic Shares Outstanding | 8.00B | 8.08B | 8.14B | 8.19B | 8.24B |
| Average Diluted Shares Outstanding | 8.06B | 8.13B | 8.19B | 8.24B | 8.29B |
| Dividend Per Share | 3.86 | 3.86 | 3.92 | 3.92 | 3.92 |
| Payout Ratio | 60.27% | 63.85% | 43.31% | 47.13% | 34.16% |